NCT07000383View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

March 31, 2026

Conditions
Diarrhea-predominant Irritable Bowel SyndromeIrritable Bowel Syndrome of Diarrhea Type (IBS-D)
Interventions
DEVICE

Gelsectan

Gelsectan is a medical device containing xyloglucan, pea protein, and tannins, administered orally. Dosage: 2 capsules BID during Month 1, followed by 1 capsule BID during Month 2.

DRUG

Antispasmodic Agent

An oral antispasmodic medication, prescribed according to standard clinical practice for IBS-D.

Trial Locations (1)

700000

RECRUITING

University Medical Center Ho Chi Minh City, Ho Chi Minh City

All Listed Sponsors
lead

University Medical Center Ho Chi Minh City (UMC)

OTHER

NCT07000383 - Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter